Adamas Pharmaceuticals (ADMS) PT Lowered to $23 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Needham & Company Downgrades Adamas Pharmaceuticals (ADMS) to Hold
March 5, 2019 7:35 AM ESTNeedham & Company analyst Serge Belanger downgraded Adamas Pharmaceuticals (NASDAQ: ADMS) from Buy to Hold.
The analyst commented, "Gocovri ended 2018 with 4Q18 sales of $13.3MM (+25%Q/Q) via 5,730 fulfilled Rxs (+21%Q/Q) and was expected to double its market share to ~2% in... More
Mizuho Securities Downgrades Adamas Pharmaceuticals (ADMS) to Underperform
March 5, 2019 6:24 AM ESTMizuho Securities analyst Irina Koffler downgraded Adamas Pharmaceuticals (NASDAQ: ADMS) from Neutral to Underperform with a price target of $5.00 (from $11.00) after guidance was withdrawn.
we believe the launch is likely going even worse than we thoughtWe now model $58.5M in 2019... More